Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.
CEO Dr. Yousef speaks about “The Science of Longevity: Stopping Aging at the Cellular Level to Prevent Disease and Improve Quality of Life” as an invited panelist for the 2023 Biotech Showcase.
CEO Dr. Hanadie Yousef discussed the convergence of AI, healthcare, and longevity in early November in Paris at JPM 40×40 as an invited speaker amongst a curated group of global business leaders across all sectors.
CEO, Dr. Yousef presented Juvena’s approach to mining the regenerative secretomes of human pluripotent stem cells to identify and develop novel disease-modifying biologics that promote tissue regeneration and repair in order to rejuvenate lives as the 14th annual drug discovery strategic summit this year.
Congratulations to Juvena Therapeutics Co-Founder and CEO Dr. Yousef for being named a “Big Think” speaker at #BioFuture2023 in recognition of the company’s accelerated growth and momentum in addressing a long-standing critical gap in drug discovery by unlocking the therapeutic potential of secreted proteins in order to develop regenerative therapeutics.
Our Director of Discovery and Platform, Dr. Thach Mai and CSO Dr. Jeremy O’Connell share more about Juvena’s discovery platform and approach to identifying and developing a regenerative biologics for promoting lung epithelium re-growth for the treatment of idiopathic pulmonary fibrosis at the IPF 2023 Annual summit.
Juvena is delighted to have had the opportunity to participate in the Mubadala Capital Singapore Forum. CEO Dr. Yousef was on the panel, “The New Frontier of Biotech Investing & Company Creation”
